Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 22, 2011 - Issue 3
Submit an article Journal homepage
119
Views
18
CrossRef citations to date
0
Altmetric
Case series and reports

Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: Three cases with relevant improvement under voriconazole therapy

Paulo Ricardo CriadoDermatology Department, School of Medicine, University of Sao Paulo, Sao Paulo, BrazilCorrespondence[email protected]
,
Mariana Figueiroa CaretaDermatology Department, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
,
Neusa Y. S. ValenteDermatology Department, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
,
José Eduardo Costa MartinsDermatology Department, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
,
Evandro A. RivittiDermatology Department, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
,
Ricardo SpinaDermatology Department, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
&
Walter BeldA JrDermatology Department, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
 show all
Pages 167-174 | Received 24 Sep 2009, Accepted 29 Nov 2009, Published online: 28 Jul 2010

References

  • Paniz-Mondolfi AE, Colella MT, Negrín DC, Aranzazu N, Oliver M, Reyes-Jaimes O, Extensive chromoblastomycosis caused by Fonsecaea pedrosoi successfully treated with a combination of amphotericin B and itraconazole. Med Mycol. 2008;46(2):179–184.
  • Sayal SK, Prasad GK, Jawed KZ, Sanghi S, Satyanarayana S. Chromoblastomycosis. Indian J Dermatol Venereol Leprol. 2002;68:233–234.
  • Franzen AJ, Cunha MM, Miranda K, Hentschel J, Plattner H, da Silva MB, Ultrastructural characterization of melanosomes of the human pathogenic fungus Fonsecaea pedrosoi. J Struct Biol. 2008;162(1):75–84.
  • Damian DL, Barnetson RS, Thompson JF. Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg. 2006;10(1):48–51.
  • Gimenes VM, Criado PR, Martins JE, Almeida SR. Cellular immune response of patients with chromoblastomycosis undergoing antifungal therapy. Mycopathologia. 2006; 162(2):97–101.
  • Tuffanelli I, Milburn PB. Treatment of chromoblastomycosis. J Am Acad Dermotol. 1991;25(5 Pt 1):869–870.
  • Smith C, Barker J, Hay R. A case of chromoblastomycosis responding to treatment with itraconazole. Br J Dermatol. 1993;128:436–439.
  • Queiroz-Telles F, Purim KS, Fillus JN, Bordignon GF, Lameira RP, Van Cutsem J, Cauwenbergh G. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol. 1992;31:805–812.
  • Andrade TS, Castro LG, Nunes RS, Gimenes VM, Cury AE. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses. 2004;47:216–221.
  • Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: Novel perspectives. Curr Opin Infect Dis. 2006; 19(2):148–152.
  • Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: An in vitro comparison. J Am Acad Dermatol. 1998;38:37–41.
  • Gupta AK, Taborda PR, Danzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529–534.
  • Bonifaz A, Paredes-Sólis V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother. 2004;5:247–254.
  • Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am. 2003;17(1): 59–85.
  • Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(suppl 1):1–10.
  • Hamza SH, Mercado PJ, Skelton HG, Smith KJ. An unusual dematiaceous fungal infection of the skin caused by Fonsecaea pedrosoi: A case report and review of the literature. J Cutan Pathol. 2003;30(5):340–343.
  • Surash S, Tyagi A, De Hoog GS, Zeng JS, Barton RC, Hobson RP. Cerebral phaeohyphomycosis caused by Fonsecaea monophora. Med Mycol. 2005;43(5):465–472.
  • Perfect J, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122–1131.
  • Paugam A. The latest data on posaconazole. Med Mal Infect. 2007;37(2):71–76.
  • Jurkunas UV, Langston DP, Colby K. Use of voriconazole in the treatment of fungal keratitis. Int Ophthalmol Clin. 2007;47(2):47–59.
  • Da Silva JP, Alviano DS, Alviano CS, de Souza W, Travassos LR, Diniz JA, Comparison of Fonsecaea pedrosoi sclerotic cells obtained in vivo and in vitro: Ultrastructure and antigenicity. FEMS Immunol Med Microbiol. 2002;33(1):63–69.
  • Sabo JA, Abdel-Rahman SM. Voriconazole: A new traizole antifungal. Ann Pharmacother. 2000;34:1032–1043.
  • Johnson L, Kauffman C. Voriconazole: A new triazole antifungal agent. Clin Infect Dis. 2003;36:630–637.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.